| __timestamp | Protagonist Therapeutics, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7459000 | 396000000 |
| Thursday, January 1, 2015 | 11831000 | 364000000 |
| Friday, January 1, 2016 | 25705000 | 376000000 |
| Sunday, January 1, 2017 | 46181000 | 382000000 |
| Monday, January 1, 2018 | 59497000 | 432000000 |
| Tuesday, January 1, 2019 | 65003000 | 457000000 |
| Wednesday, January 1, 2020 | 74506000 | 463000000 |
| Friday, January 1, 2021 | 126006000 | 508000000 |
| Saturday, January 1, 2022 | 126215000 | 539000000 |
| Sunday, January 1, 2023 | 120161000 | 614000000 |
| Monday, January 1, 2024 | 686000000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, strategic investment in research and development (R&D) is crucial. Over the past decade, Zoetis Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting approaches to R&D spending. From 2014 to 2023, Zoetis Inc. consistently allocated a significant portion of its resources to R&D, with expenditures peaking at approximately $614 million in 2023, marking a 55% increase from 2014. This robust investment underscores Zoetis's commitment to innovation and maintaining its market leadership.
Conversely, Protagonist Therapeutics, Inc. exhibited a more dynamic growth in R&D spending, with a remarkable 1,500% increase from 2014 to 2023, reaching around $120 million. This surge reflects Protagonist's aggressive strategy to enhance its research capabilities and expand its therapeutic pipeline. The data highlights the diverse strategies of these companies in navigating the ever-evolving pharmaceutical industry.
Johnson & Johnson vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Zoetis Inc. and Viatris Inc.
Research and Development Investment: Zoetis Inc. vs Catalyst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Zoetis Inc. vs Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Zoetis Inc. vs MorphoSys AG
Research and Development: Comparing Key Metrics for Zoetis Inc. and BioCryst Pharmaceuticals, Inc.
R&D Insights: How Genmab A/S and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Investment: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc.
R&D Spending Showdown: Ionis Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.
R&D Spending Showdown: TG Therapeutics, Inc. vs Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Mesoblast Limited: Who Invests More in Innovation?
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.